What is the current Monoclonal Antibody for Multiple Myeloma market size?

The Monoclonal Antibody for Multiple Myeloma market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Monoclonal Antibody for Multiple Myeloma market?

Key drivers include rising prevalence of multiple myeloma and growing adoption of monoclonal antibodies.

What are the major challenges facing the market?

Challenges include high development costs and intense competition among market players.

Which regions are expected to lead the Monoclonal Antibody for Multiple Myeloma market?

North America and Europe are expected to be regional leaders due to strong healthcare infrastructure.

Who are the top companies in the Monoclonal Antibody for Multiple Myeloma market?

Top companies include Johnson & Johnson, Pfizer, and Roche, which offer a range of monoclonal antibody products.

What future opportunities exist in the Monoclonal Antibody for Multiple Myeloma market?

Future opportunities include emerging markets and increasing use of combination therapies.

How will technology impact the Monoclonal Antibody for Multiple Myeloma market?

Advances in technology will improve manufacturing efficiency and reduce costs, driving market growth.

What is the current regulatory landscape for the Monoclonal Antibody for Multiple Myeloma market?

The regulatory landscape is characterized by strict approval processes and ongoing monitoring of product safety.

What is the future outlook for the Monoclonal Antibody for Multiple Myeloma market?

The future outlook is positive, with increasing demand and growing adoption of monoclonal antibodies expected.

Monoclonal Antibody for Multiple Myeloma Market Potential & Strategic Outlook 2033

Monoclonal Antibody for Multiple Myeloma by Type (/> Elotuzumab, Daratumumab, Siltuximab, Dacetuzumab, Rituximab, Other), by Application (/> Hospital, Drug Center, Clinic, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Monoclonal Antibody for Multiple Myeloma Market Overview

The Monoclonal Antibody for Multiple Myeloma market refers to the industry focused on developing and marketing monoclonal antibodies for the treatment of multiple myeloma, a type of blood cancer. As the Monoclonal Antibody for Multiple Myeloma market size is expected to grow significantly, driven by increasing demand for effective treatments, the growth outlook and market forecast are crucial for industry stakeholders. The global Monoclonal Antibody for Multiple Myeloma market size was approximately $12.7 billion in 2025 and is projected to reach $24.4 billion by 2033, at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period.

Loading chart…

Key forces shaping the industry include technology shifts towards more targeted and personalized therapies, regulatory approvals for new treatments, and changing consumer behavior driven by increasing awareness about multiple myeloma. The largest region for the Monoclonal Antibody for Multiple Myeloma market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rising healthcare expenditure and growing demand for cancer treatments. As the industry continues to expand, driven by industry expansion and market forecast, stakeholders must stay informed about the latest developments and trends to remain competitive.

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	27.40 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol Myers Squibb; Abbvie; Janssen Biotech; Karyopharm Therapeutics; PDL BioPharma; Roche; Seattle Genetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Monoclonal Antibody for Multiple Myeloma market is poised for significant growth, driven by increasing demand for effective treatments and a rising prevalence of multiple myeloma cases. The Monoclonal Antibody for Multiple Myeloma market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advancements in biotechnology and genetic engineering have enabled the development of more targeted and potent monoclonal antibodies, driving innovation in the Monoclonal Antibody for Multiple Myeloma market.

Increasing investments in research and development, coupled with favorable government initiatives, are fueling the growth of the Monoclonal Antibody for Multiple Myeloma market size.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Monoclonal Antibody for Multiple Myeloma market, thereby restricting its growth.

The complexity of manufacturing processes and the need for specialized facilities are also hindering the expansion of the Monoclonal Antibody for Multiple Myeloma market.

Opportunities2 items

Emerging markets, particularly in Asia-Pacific and Latin America, offer significant opportunities for the Monoclonal Antibody for Multiple Myeloma market due to their large patient populations and increasing healthcare expenditures.

The growing focus on personalized medicine and targeted therapies is expected to drive demand for monoclonal antibodies, leading to a positive growth forecast for the Monoclonal Antibody for Multiple Myeloma market.

Challenges2 items

The Monoclonal Antibody for Multiple Myeloma market faces intense competition, with several established players and new entrants vying for market share, which can lead to pricing pressures and reduced profit margins.

The need for continuous innovation and investment in research and development to stay ahead of the competition poses a significant challenge for companies operating in the Monoclonal Antibody for Multiple Myeloma market.

Market Segmentation

Loading chart…

The Monoclonal Antibody for Multiple Myeloma market can be segmented based on Type, which refers to the different classes of monoclonal antibodies used to treat multiple myeloma. This segmentation is crucial in understanding the Monoclonal Antibody for Multiple Myeloma segmentation as it highlights the various mechanisms of action and targets for these therapeutic agents. The main types include murine, chimeric, humanized, and human monoclonal antibodies, each with its own set of advantages and limitations.

Another significant segmentation of the Monoclonal Antibody for Multiple Myeloma market is by Application, which encompasses the different stages and types of multiple myeloma treatments where these antibodies are applied. This includes newly diagnosed multiple myeloma, relapsed or refractory multiple myeloma, and maintenance therapy. Understanding the application segment is vital for grasping the market taxonomy and how different monoclonal antibodies are preferred over others in various clinical settings.

Monoclonal Antibody for Multiple Myeloma Segmentation Breakdown12 items

Type

/> Elotuzumab

Daratumumab

Siltuximab

Dacetuzumab

Rituximab

Other

Application

/> Hospital

Drug Center

Clinic

Other

Regional Insights

Loading chart…

The Monoclonal Antibody for Multiple Myeloma market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of monoclonal antibodies, favorable government policies, and growing investments in healthcare infrastructure.

Key drivers for each region include: for North America, established healthcare infrastructure, high awareness of multiple myeloma, and strong ecosystem maturity; for Europe, rising demographics of the aging population, advancements in research and development, and regulatory support; for Asia Pacific, growing demand for effective treatments, expanding healthcare access, and increasing investments in pharmaceutical research; for Latin America, improving economy, expanding middle class, and growing healthcare expenditure; and for Middle East & Africa, rising awareness of multiple myeloma, growing healthcare infrastructure, and increasing adoption of monoclonal antibodies.

The regional forecast indicates that the Monoclonal Antibody for Multiple Myeloma market will experience significant growth, driven by increasing prevalence of multiple myeloma, advancements in technology, and growing demand for effective treatments. Understanding the regional dynamics and key drivers is crucial for stakeholders to navigate the market and capitalize on emerging opportunities.

Competitive Landscape

The Monoclonal Antibody for Multiple Myeloma market exhibits a moderately consolidated structure, driven by both global players and local companies. The Monoclonal Antibody for Multiple Myeloma competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals to maintain their market position, while local companies concentrate on pricing and distribution to compete effectively.

Companies in this market employ various strategies to differentiate themselves, including mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To overcome these challenges, companies must develop unique value propositions, such as technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategic focuses:

Bristol Myers Squibb: regional expansion

Abbvie: innovation pipeline

Janssen Biotech: premium pricing

Karyopharm Therapeutics: local manufacturing

PDL BioPharma: OEM tie-ups

Roche: vertical integration

Key Monoclonal Antibody for Multiple Myeloma Companies7 items

Bristol Myers Squibb

Abbvie

Janssen Biotech

Karyopharm Therapeutics

PDL BioPharma

Roche

Seattle Genetics

Market Ecosystem

The Monoclonal Antibody for Multiple Myeloma ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers, midstream integrators and manufacturers, to downstream channels and end users. This ecosystem is characterized by a series of interactions and relationships that create and capture value, from the development of monoclonal antibodies to their administration in clinical settings. Understanding the boundaries and dynamics of this ecosystem is crucial for navigating the Monoclonal Antibody for Multiple Myeloma ecosystem and identifying opportunities for growth and innovation.

Raw material/component suppliers — providing critical inputs

OEMs / manufacturers — developing and producing antibodies

Distributors / channel partners — ensuring product availability

Service providers / after-sales — offering support and maintenance

End users / buyers — administering treatments to patients

Regulators/standards bodies — overseeing safety and efficacy

Data/analytics providers — informing treatment decisions and research

The flow of value within the Monoclonal Antibody for Multiple Myeloma ecosystem is influenced by various control points, including regulatory approvals, reimbursement policies, and partnerships between manufacturers and distributors. Dependency risks, such as input constraints and standards compliance, can impact the availability and affordability of these treatments. Furthermore, switching costs and interoperability requirements may limit the flexibility of end users to adopt alternative products or services. As the ecosystem differs by region, with varying regulatory frameworks and market conditions, understanding these nuances is essential for effective navigation and value chain analysis.

Recent Industry Insights

The Monoclonal Antibody for Multiple Myeloma market has witnessed significant developments over the last 12-18 months, shaping the industry trends. Recently, there have been notable partnerships, such as collaborations between pharmaceutical companies to develop novel monoclonal antibody therapies. Additionally, mergers and acquisitions have also been observed, with companies looking to expand their portfolios and strengthen their positions in the market.

Furthermore, the Monoclonal Antibody for Multiple Myeloma industry trends have been influenced by product launches, with several companies introducing new treatments that have received regulatory approvals. Regulatory changes have also played a crucial role, with updates in guidelines and policies affecting the development and approval of monoclonal antibody therapies. These developments have contributed to a shift in consumer and enterprise trends, with an increased focus on targeted and personalized treatments. Funding rounds and expansions have also been reported, with investors showing interest in the potential of monoclonal antibodies for multiple myeloma treatment.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Monoclonal Antibody for Multiple Myeloma market outlook. The market attractiveness is high due to the increasing prevalence of multiple myeloma and the growing demand for effective treatments. The competitive intensity is moderate, with several key players dominating the market. The long-term outlook is promising, driven by ongoing innovation in the development of novel monoclonal antibodies.

The innovation landscape is rapidly evolving, with a focus on combination therapies and bispecific antibodies. The demand-supply balance is expected to be stable, with increasing demand met by growing supply from existing and new market entrants. Key risk factors include regulatory changes and pricing pressures. Overall, the market is expected to experience significant growth, driven by the increasing adoption of monoclonal antibodies for multiple myeloma treatment.

11 items

1. Executive Summary

2. Monoclonal Antibody for Multiple Myeloma Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Monoclonal Antibody for Multiple Myeloma Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Monoclonal Antibody for Multiple Myeloma Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Elotuzumab

6.1.2. Daratumumab

6.1.3. Siltuximab

6.1.4. Dacetuzumab

6.1.5. Rituximab

6.1.6. Other

6.2. Global Monoclonal Antibody for Multiple Myeloma Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Drug Center

6.2.3. Clinic

6.2.4. Other

6.3. Global Monoclonal Antibody for Multiple Myeloma Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Monoclonal Antibody for Multiple Myeloma Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Monoclonal Antibody for Multiple Myeloma Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Monoclonal Antibody for Multiple Myeloma Market Competition by Key Manufacturers

8.1. Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Monoclonal Antibody for Multiple Myeloma: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bristol Myers Squibb

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbvie

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Janssen Biotech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Karyopharm Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. PDL BioPharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Roche

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Seattle Genetics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Monoclonal Antibody for Multiple Myeloma Market

Figure 4: Global Monoclonal Antibody for Multiple Myeloma Market: Drivers

Figure 5: Global Monoclonal Antibody for Multiple Myeloma Market: Challenges

Figure 6: Global Monoclonal Antibody for Multiple Myeloma Market: Trends

Figure 7: Global Monoclonal Antibody for Multiple Myeloma Market: Opportunity

Figure 8: Global Monoclonal Antibody for Multiple Myeloma Market: Restraint

Figure 9: Global Monoclonal Antibody for Multiple Myeloma Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Monoclonal Antibody for Multiple Myeloma Market Value (USD Million) By Region

Figure 15: Global Monoclonal Antibody for Multiple Myeloma Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Monoclonal Antibody for Multiple Myeloma Market Value (USD Million) By Region

Figure 23: Global Monoclonal Antibody for Multiple Myeloma Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Monoclonal Antibody for Multiple Myeloma Market Value (USD Million) By Region

Table 10: Global Monoclonal Antibody for Multiple Myeloma Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Monoclonal Antibody for Multiple Myeloma Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Monoclonal Antibody for Multiple Myeloma Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Monoclonal Antibody for Multiple Myeloma Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bristol Myers Squibb Basic Information And Sales Area

Table 31: Bristol Myers Squibb. Products Portfolio

Table 32: Abbvie Basic Information And Sales Area

Table 33: Abbvie. Products Portfolio

Table 34: Janssen Biotech Basic Information And Sales Area

Table 35: Janssen Biotech. Products Portfolio

Table 36: Karyopharm Therapeutics Basic Information And Sales Area

Table 37: Karyopharm Therapeutics. Products Portfolio

Table 38: PDL BioPharma Basic Information And Sales Area

Table 39: PDL BioPharma. Products Portfolio

Table 40: Roche Basic Information And Sales Area

Table 41: Roche. Products Portfolio

Table 42: Seattle Genetics Basic Information And Sales Area

Table 43: Seattle Genetics. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Type

Table 45: Global Market Share (%) By Type (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Monoclonal Antibody for Multiple Myeloma Market Value (USD Million) By Region

Table 49: Global Monoclonal Antibody for Multiple Myeloma Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Type

Table 52: North America Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Type

Table 55: Europe Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Type

Table 61: South America Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Monoclonal Antibody for Multiple Myeloma Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	27.40 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol Myers Squibb; Abbvie; Janssen Biotech; Karyopharm Therapeutics; PDL BioPharma; Roche; Seattle Genetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing investments in research and development, coupled with favorable government initiatives, are fueling the growth of the Monoclonal Antibody for Multiple Myeloma market size.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Monoclonal Antibody for Multiple Myeloma market, thereby restricting its growth.

The complexity of manufacturing processes and the need for specialized facilities are also hindering the expansion of the Monoclonal Antibody for Multiple Myeloma market.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Monoclonal Antibody for Multiple Myeloma Segmentation Breakdown12 items

Type

/> Elotuzumab

Daratumumab

Siltuximab

Dacetuzumab

Rituximab

Other

Application

/> Hospital

Drug Center

Clinic

Other

Regional Insights

Loading chart…

Competitive Landscape

Bristol Myers Squibb: regional expansion

Abbvie: innovation pipeline

Janssen Biotech: premium pricing

Karyopharm Therapeutics: local manufacturing

PDL BioPharma: OEM tie-ups

Roche: vertical integration

Key Monoclonal Antibody for Multiple Myeloma Companies7 items

Bristol Myers Squibb

Abbvie

Janssen Biotech

Karyopharm Therapeutics

PDL BioPharma

Roche

Seattle Genetics

Market Ecosystem

Raw material/component suppliers — providing critical inputs

OEMs / manufacturers — developing and producing antibodies

Distributors / channel partners — ensuring product availability

Service providers / after-sales — offering support and maintenance

End users / buyers — administering treatments to patients

Regulators/standards bodies — overseeing safety and efficacy

Data/analytics providers — informing treatment decisions and research

Recent Industry Insights

Analyst Overview

Table of Contents